Hair Thinning: What Could Be Causing It and How to Find Out

How Common Is Hair Thinning, and Who Gets It?

Hair thinning is one of the most frequently reported concerns in both primary care and dermatology settings. Roughly 80 million adults in the United States experience some form of pattern hair loss alone, according to the American Academy of Dermatology. The condition crosses every demographic line, though presentation and underlying cause vary by age, sex, and hormonal status.

Age and Sex Patterns

Androgenetic alopecia (AGA) accounts for the largest share. A cross-sectional survey published in the Journal of the American Academy of Dermatology found that 42% of men aged 18 to 49 reported moderate-to-extensive hair loss [1]. Among postmenopausal women, prevalence estimates range from 29% to over 40% depending on the population studied [2]. Women typically notice diffuse thinning across the crown, while men more often see bitemporal recession and vertex balding.

Why It Matters Beyond Cosmetics

Thinning hair can signal systemic disease. Thyroid disorders, iron-deficiency anemia, autoimmune conditions, and hormonal imbalances all surface through changes in hair density. Dismissing thinning as purely cosmetic risks missing a treatable medical condition.

The Five Most Common Causes

Most cases of hair thinning fall into a short list of diagnoses. Understanding each one helps clarify why your doctor orders specific labs and how treatment choices differ.

Androgenetic Alopecia (Pattern Hair Loss)

This is the single most frequent cause in both sexes. Dihydrotestosterone (DHT) miniaturizes genetically susceptible follicles over years, gradually converting thick terminal hairs into fine vellus hairs. A 2014 meta-analysis in the Journal of the American Academy of Dermatology confirmed that finasteride 1 mg daily reduced hair loss progression in 83% of men over two years compared with 28% on placebo [3]. For women, the Endocrine Society recommends against finasteride in premenopausal women of childbearing potential due to teratogenicity; topical minoxidil remains first-line [4].

Telogen Effluvium

A shock to the system pushes a disproportionate number of follicles from the growth phase (anagen) into the resting phase (telogen) simultaneously. Common triggers include childbirth, high fever, surgery, crash dieting, and severe psychological stress. Shedding typically begins two to three months after the triggering event. The reassuring feature: telogen effluvium is almost always self-limiting, with full regrowth within six to nine months once the trigger resolves [5].

Thyroid Dysfunction

Both hypothyroidism and hyperthyroidism cause diffuse hair thinning. Thyroid hormone directly regulates the hair cycle. A study in the Indian Journal of Endocrinology and Metabolism found that 30% of hypothyroid patients presented with hair loss as a chief complaint, and hair regrowth followed normalization of TSH in most cases [6]. If you are losing hair and also experiencing fatigue, weight changes, or cold intolerance, thyroid screening is warranted [7].

Iron Deficiency

Ferritin levels below 30 ng/mL are associated with increased hair shedding even in the absence of frank anemia. A 2006 study in the Journal of the American Academy of Dermatology (N=5,110) found that women with diffuse hair loss had significantly lower mean ferritin than controls (p<0.001) [8]. Dr. Leonid Benjamin Trost of the Cleveland Clinic has noted: "Treatment of iron deficiency may represent a critical component of managing hair loss in women, and ferritin should be checked in every woman presenting with diffuse thinning." Oral iron supplementation typically takes three to six months to show visible improvement in hair density.

Alopecia Areata

This autoimmune condition produces well-demarcated, round patches of complete hair loss. It affects roughly 2% of the global population at some point in their lifetime [9]. In 2022, the FDA approved baricitinib (Olumiant) for adults with severe alopecia areata, and ritlecitinib (Litfulo) followed in 2023 for patients aged 12 and older. The BRAVE-AA1 trial (N=654) showed that baricitinib 4 mg daily achieved ≥80% scalp hair coverage in 35.2% of patients at week 36 versus 5.3% on placebo [10].

Less Common but Important Causes

Not every case fits neatly into the top five. Several other conditions deserve a mention because missing them delays appropriate treatment.

Nutritional Deficiencies Beyond Iron

Zinc, biotin, vitamin D, and essential fatty acid deficiencies can all contribute to thinning. A 2019 systematic review in Dermatology and Therapy found that vitamin D levels below 20 ng/mL correlated with both telogen effluvium and female pattern hair loss [11]. Supplementing without confirming a deficiency is not recommended, since excess vitamin A and selenium can paradoxically worsen hair loss.

Medication-Induced Hair Loss

Several drug classes cause thinning as a side effect. These include certain anticoagulants (heparin, warfarin), retinoids (isotretinoin), antithyroid medications, beta-blockers, lithium, valproic acid, and some antidepressants. The pattern usually mimics telogen effluvium. Identifying the offending drug is critical, because discontinuation or substitution often reverses the shedding [12].

Hormonal Shifts: PCOS and Menopause

Polycystic ovary syndrome (PCOS) produces androgen excess, which drives a female-pattern thinning that can begin in the teens or twenties. Postmenopausal estrogen decline similarly accelerates follicle miniaturization. The American Association of Clinical Endocrinology (AACE) guidelines recommend screening for PCOS in any young woman with thinning hair, acne, and irregular cycles [13].

Scalp Conditions

Seborrheic dermatitis, psoriasis, and fungal infections (tinea capitis) inflame the scalp and can thin hair mechanically. These are diagnosed on physical exam. Treatment of the underlying dermatosis allows follicles to recover.

How Doctors Diagnose the Cause

A structured workup narrows the differential quickly. Most dermatologists and endocrinologists follow a two-step approach: history and exam first, then targeted labs.

Clinical History and Examination

Your doctor will ask about the timeline of shedding, recent life stressors, medication changes, diet, menstrual history (in women), and family history of baldness. The physical exam focuses on the pattern of loss (diffuse versus patchy), the presence of scaling or erythema, and a "pull test" where gentle traction on 40 to 60 hairs gauges whether active shedding exceeds the normal threshold. Dermoscopy (a handheld magnifying device with polarized light) reveals miniaturized hairs, exclamation-point hairs (alopecia areata), or perifollicular scaling.

Laboratory Panel

The British Association of Dermatologists' 2023 guidelines recommend the following baseline labs for unexplained hair thinning [14]:

• Complete blood count (CBC) to screen for anemia
• Ferritin (target ≥ 40 ng/mL for optimal hair growth)
• TSH and free T4 for thyroid function
• Vitamin D (25-OH) level
• Zinc level
• DHEA-S, total testosterone, free testosterone if androgen excess is suspected
• ANA if autoimmune disease is considered

A scalp biopsy is reserved for cases where the clinical picture and labs are inconclusive. The biopsy distinguishes scarring from non-scarring alopecia, a distinction that changes the treatment plan entirely.

Evidence-Based Treatment Options

Treatment depends on the diagnosis. No single therapy works for all types of thinning.

For Androgenetic Alopecia

Minoxidil (topical 5% solution or foam) is the most widely studied topical agent. A Cochrane review of 47 trials found that topical minoxidil increased hair count by a mean of 14.94 hairs/cm² more than placebo at 24 weeks [15]. It works by prolonging anagen and increasing follicle diameter. Side effects include scalp irritation and, rarely, unwanted facial hair growth.

Finasteride (1 mg oral daily) blocks the conversion of testosterone to DHT. The key phase III trials showed a 107-hair increase per 1-inch diameter circle of scalp at 12 months versus a 55-hair decrease in the placebo group [3]. Off-label use at 2.5 to 5 mg daily in postmenopausal women has shown promise in small trials, but data remain limited.

Low-level laser therapy (LLLT) received FDA clearance as an adjunct. A 2014 randomized controlled trial (N=128) published in the American Journal of Clinical Dermatology reported a 20.2-hair/cm² increase in the treated group versus 2.8 in sham controls at 26 weeks [16].

For Telogen Effluvium

No specific pharmacotherapy exists. Remove the trigger, correct any nutritional deficiencies found on labs, and wait. Reassurance is the primary intervention. If shedding persists beyond six months, the diagnosis should be reconsidered.

For Thyroid-Related Thinning

Normalizing thyroid hormone levels with levothyroxine (hypothyroid) or methimazole/propylthiouracil (hyperthyroid) typically restores hair over three to six months. The American Thyroid Association recommends targeting a TSH of 0.5 to 2.5 mIU/L for most adults on replacement therapy [17].

For Iron Deficiency

Oral ferrous sulfate 325 mg daily (providing ~65 mg elemental iron) taken on an empty stomach with vitamin C improves absorption. Recheck ferritin at 8 to 12 weeks. The target for hair regrowth is a ferritin above 40 ng/mL, though some specialists aim for above 70 ng/mL in refractory cases [8].

For Alopecia Areata

Topical or intralesional corticosteroids remain first-line for limited disease. For extensive cases, the JAK inhibitors baricitinib and ritlecitinib represent a significant advance. The ALLEGRO-2b/3 trial (N=718) demonstrated that ritlecitinib 50 mg daily achieved ≥80% scalp coverage in 23.0% of patients at 24 weeks versus 1.6% on placebo [18].

When to Seek Medical Evaluation

Not every shed hair warrants a doctor visit. But certain patterns signal that something beyond normal cycling is happening.

Red Flags That Need Prompt Attention

• Sudden onset of shedding (handfuls in the shower, clumps on the pillow)
• Patchy, well-circumscribed bald spots
• Hair loss accompanied by scalp pain, burning, or scarring
• Thinning paired with new symptoms: fatigue, weight change, irregular periods, or joint pain
• Progressive thinning in a woman under 30 without family history

The 100-Hair Rule

Shedding up to 100 hairs daily is physiologically normal. One practical self-test: collect all hairs shed during a morning shampoo for three consecutive washes. If the average count exceeds 100, or if the number is rising sharply, consider getting a lab panel. Dr. Amy McMichael, professor of dermatology at Wake Forest School of Medicine, has stated: "Patients often think any hair in the drain is abnormal. Quantifying shedding removes anxiety and helps us focus on cases that genuinely need intervention."

Lifestyle Factors That Influence Hair Density

Medical treatment addresses the root cause, but daily habits affect how quickly hair recovers and how well it holds.

Protein and Micronutrient Intake

Hair is 95% keratin, a protein. Diets providing fewer than 0.8 g protein per kilogram of body weight per day may impair hair synthesis. The World Health Organization protein recommendations provide a floor, but physically active adults and those recovering from telogen effluvium may benefit from 1.0 to 1.2 g/kg/day.

Traction and Styling Damage

Tight ponytails, braids, weaves, and extensions create sustained tension on follicles. Over years, this causes traction alopecia, a form of hair loss that becomes permanent if the traction continues long enough for follicles to scar. Early recognition and loosening hairstyles can allow full recovery.

Stress Management

Chronic psychological stress elevates cortisol, which can shift follicles prematurely into telogen. A 2021 study in Nature identified that corticosterone (the mouse analog of cortisol) directly suppresses dermal papilla cell function, providing a molecular mechanism for stress-induced hair loss [19]. Interventions as simple as regular aerobic exercise have shown benefit in reducing cortisol levels.

Emerging Therapies on the Horizon

Several new approaches are in late-stage clinical trials. Clascoterone, a topical antiandrogen already FDA-approved for acne (Winlevi), is being studied for androgenetic alopecia. Oral minoxidil at low doses (0.625 to 5 mg daily) has gained traction in clinical practice, with a 2022 retrospective in JAAD (N=1,404) showing 66% of patients reporting improvement at a median follow-up of one year [20]. Platelet-rich plasma (PRP) injections, while lacking FDA approval for hair loss specifically, have shown statistically significant increases in hair density in several small randomized trials [21].

The first step for anyone experiencing hair thinning remains a focused lab panel (CBC, ferritin, TSH, free T4, vitamin D, zinc) and a clinical exam with dermoscopy. This combination identifies the cause in the majority of cases and points directly to an evidence-based treatment plan.